MTOR and hepatocellular carcinoma: In addition, activation of mammalian target of rapamycin (mTOR) appears to be associated with less differentiated tumors, poor survival and early recurrence after surgical resection and an impaired overall prognosis in advanced HCC [29,30,31,32].